Congratulations to HistoSonics and Venture Investors Health Fund!
Today is the day. 🎉 HistoSonics, Inc. has just announced a $2.25 billion acquisition by a global consortium of investors—including K5 Global, Bezos Expeditions, and Wellington Management. This is the largest exit in Venture Investors Health Fund history—and one that hits close to home. This milestone shows what’s possible when breakthrough science meets patient need. Histotripsy, their non-invasive, non-toxic therapy, delivers focused ultrasound to destroy tumors and has truly changed the standard of care for patients. We’ve believed in this company since the beginning. Our own Jim Adox helped guide the company from University of Michigan spinout to global force, served as Board Chair, and will remain on the board. VI led HistoSonics’ Series A, Series B, and has participated in every subsequent funding round. This is what it looks like to build life-changing healthcare companies in the Midwest—with national impact and global potential. And we’re not done: VI remains a proud investor and long-term partner to HistoSonics as they scale to new indications, new markets, and new patients. Histotripsy isn’t just the future of surgery—it’s the future of hope. 📰 WSJ article by Brian Gormley [paywall]: https://lnkd.in/gpnQmCwi 📣 Press release: https://lnkd.in/eHNnGuAM Congratulations to Mike Blue and the entire HistoSonics team—and to every patient and family this will touch. Jim Adox Joseph Amaral Jenni Le David Arnstein John Neis Scott Button Paul Weiss Joshua Stopek David Krenn Michele Bazinet-Bossert Dan Kosednar Donald Hayden Joseph Herman Josh King Barb Peterson Amanda Cafaro #Histotripsy #HealthcareInnovation #VentureCapital #MidwestInnovation #LifeSciences